However, future prospective studies of RT in the early phase of TKI initial treatment in NSCLC are imperative, as it remains unknown whether or not RT before or after chemotherapy provides better survival outcomes in patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.